Business UpdateMay 18, 2026, 12:17 PM
Tevogen Reduces Loss from Operations by 51% in FY2025, 48% in Q1 2026
AI Summary
Tevogen Bio Holdings Inc. reported significant operational improvements, with loss from operations declining 51% to $26.1 million in full year 2025 from $53.6 million in 2024. This positive trend continued into Q1 2026, with a 48% improvement to $5.4 million. The company also advanced strategic initiatives, including establishing Tevogen.AI and expanding its cell therapy pipeline, while evaluating potential revenue-generating acquisitions and maintaining disciplined capital allocation to protect shareholder equity.
Key Highlights
- Loss from operations declined 51% to $26.1 million in FY2025 from $53.6 million in FY2024.
- Q1 2026 loss from operations decreased 48% to $5.4 million compared to Q1 2025.
- Established the Tevogen.AI effort.
- Continued expansion of the cell therapy product pipeline.
- Initiated evaluation of potential revenue-generating acquisitions.
- Maintained disciplined capital allocation to avoid shareholder dilution.
- Working to align long-term incentives with performance milestones, including revenue generation.
Price Impact
More from TVGN